# US 2012/0258872 A1 · Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0258872 A1
- Document ID: US20120258872A1
- Status: Published application
- Kind: A1
- Application number: 13/164,546
- Filed: 2011-06-20
- Published: 2012-10-11
- Earliest claimed: 2002-07-24
- Inventors: André Delacourte; Nicolas Sergeant
- Web page: https://patentgrep.com/patent/US20120258872A1

## CPC

- A61K 39/0007: {Nervous system antigens; Prions}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- C07K 16/18: against material from animals or humans
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2800/2821: Alzheimer
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides compositions and methods for prevention and treatment of diseases associated with β-amyloid formation and/or aggregation. Such methods encompass the induction of an immune response against N-terminal truncated and/or post-translationally modified Aβ peptides. These peptides are further used in compositions and methods for the diagnosis of diseases associated with β-amyloid formation and/or aggregation.

## Claims

### Claim at position 1

-25. (canceled)

### Claim 26

A method for determining, in a patient, the susceptibility to a disease associated with β-amyloid formation and/or aggregation, for determining, the risk of developing a disease associated with β-amyloid formation and/or aggregation, for screening of the clearance of β-amyloid deposition, and/or for predicting the level of β-amyloid burden, said method comprising:
(a) determining, in a sample of brain extract or cerebrospinal fluid obtained from said patient, the amount of N-terminal truncated and/or post-translationally modified β-amyloid 42 variant or an N-terminal fragment thereof, the amount of C-terminal extended N-terminal APP soluble fragment or a C-terminal fragment thereof, or the amount of antibody or reactive T-cells specific for said β-amyloid variant or N-terminal fragment thereof or said APP soluble fragment or C-terminal fragment thereof;
(b) comparing the amount determined in step (a) with the amount of said N-terminal truncated and/or post-translationally modified β-amyloid variant or an N-terminal fragment thereof, the amount of C-terminal extended N-terminal APP soluble fragment or a C-terminal fragment thereof, or the amount of antibody or reactive T-cells specific for said β-amyloid variant or an N-terminal fragment thereof or said APP soluble fragment or a C-terminal fragment thereof in a control sample obtained from a control population known not to suffer said disease; and
(c) concluding, from the comparison in step (b), whether the patient is susceptible to a disease associated with β-amyloid formation and/or aggregation, whether the patient is at risk of developing a disease associated with β-amyloid formation and/or aggregation, whether the β-amyloid deposition in the patient is cleared, or what the level of β-amyloid burden is in said patient.

### Claim at position 3

-28. (canceled)

### Claim 29 (depends on 26)

The method of claim 26 comprising:
(a) determining in the patient sample, the amount of N-terminal truncated and/or post-translationally modified β-amyloid 42 variant or an N-terminal fragment thereof or the amount of C-terminal extended N-terminal APP soluble fragment or a C-terminal fragment thereof;
(b) comparing the amount determined in step (a) with the amount of N-terminal truncated and/or post-translationally modified β-amyloid 42 variant or an N-terminal fragment thereof or the amount of C-terminal extended N-terminal APP soluble fragment or a C-terminal fragment thereof, in the control sample; and
(c) concluding, from the comparison of step (b), whether the patient is susceptible to a disease associated with β-amyloid formation and/or aggregation, whether the patient is at risk of developing a disease associated with β-amyloid formation and/or aggregation, whether the β-amyloid deposition in the patient is cleared, and/or what the level of β-amyloid burden is in the patient.

### Claim 30 (depends on 29)

The method of claim 29 for predicting the level of β-amyloid burden in a patient, the method comprising:
(a) administering to said patient a composition for eliciting an immune response or a composition comprising an antibody or a reactive T-cell that specifically recognizes an N-terminal truncated and/or post-translationally modified Aβ peptide or an N-terminal fragment thereof, or a composition comprising a nucleic acid preparation encoding an N-terminal truncated and/or post-translational modified Aβ peptide or an N-terminal fragment thereof;
(b) determining in a sample or brain extract or cerebrospinal fluid obtained from said patient the amount of N-terminal truncated and/or post-translationally modified β-amyloid 42 variant or an N-terminal fragment thereof;
(c) comparing the amount determined in step (b) with the amount of N-terminal truncated and/or post-translationally modified β-amyloid 42 variant or an N-terminal fragment thereof in a control sample obtained from a control population; and
(d) concluding from the comparison in step (c) what the level of β-amyloid burden is in said patient.

### Claim 31 (depends on 26)

The method of claim 26 wherein said N-terminal truncated β-amyloid variant is selected from the group consisting of Aβ(2-42), Aβ(3-42), Aβ(4-42), Aβ(5-42), Aβ(6-42), Aβ(7-42), Aβ(8-42), Aβ(9-42) and Aβ(10-42).

### Claim 32 (depends on 31)

The method of claim 31 wherein said N-terminal truncated β-amyloid variant starts at position 2, 3, 4, 5, 8 or 9.

### Claim 33 (depends on 26)

The method of claim 26 wherein the post-translationally modified β-amyloid variant is modified by methylation or pyroglutamylation.

### Claim 34 (depends on 33)

The method of claim 33 wherein the methylation is present at position 1, 2, 4, or 6 of an N-terminal truncated β-amyloid variant.

### Claim 35 (depends on 34)

The method according to claim 34 further characterized in that the pyroglutamylation is present at position 3 of an N-terminal truncated β-amyloid variant starting at position 3 of β-amyloid.

### Claim 36 (depends on 26)

The method of claim 26 wherein the C-terminal end of said C-terminal extended N-terminal APP soluble fragment consists of position 1, 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 8, or 1 to 9 of β-amyloid.

### Claim 37 (depends on 26)

The method of claim 26 for determining in a patient, the susceptibility to a disease associated with β-amyloid formation and/or aggregation, or for determining, in a patient, the risk of developing a disease associated with β-amyloid formation and/or aggregation comprising:
(a) determining, in a sample obtained from said patient: the amount of antibody or reactive T-cells specific for an N-terminal truncated and/or post-translationally modified Aβ peptide or an N-terminal fragment thereof, and/or specific for an C-terminal extended N-terminal APP soluble fragment, or a C-terminal fragment thereof;
(b) comparing the amount determined in step (a) with the amount of the antibody or reactive T-cells in a control population; and
(c) concluding, from the comparison in step (b), whether the patient is susceptible to a disease associated with β-amyloid formation and/or aggregation or whether the patient is at risk of developing a disease associated with β-amyloid formation and/or aggregation;
wherein an increased amount of antibody or reactive T-cells specific for (i) N-terminal truncated and/or post-translationally modified Aβ peptide or for an N-terminal fragment thereof; and/or (ii) for C-terminal extended N-terminal APP soluble fragment, or for a C-terminal fragment thereof, is an indication that the patient is susceptible to, or at risk of, developing a disease associated with Aβ formation and/or aggregation.

### Claim 38 (depends on 26)

The method of claim 26 wherein the disease associated with β-amyloid formation and/or aggregation is Alzheimer's disease (AD).

### Claim 39 (depends on 38)

The method of claim 38 wherein the susceptibility to Alzheimer's disease (AD) or the risk of developing AD is determined by detecting Aβ(4-42), Aβ(5-42) or Aβ(8-42).
